The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

Last updated: August 25, 2021
Sponsor: Aristotle University Of Thessaloniki
Overall Status: Active - Recruiting

Phase

4

Condition

Alzheimer's Disease

Memory Problems

Dementia

Treatment

N/A

Clinical Study ID

NCT05022186
65/06-02-2021
  • Ages 65-85
  • All Genders

Study Summary

A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers. Ninety patients will be recruited and they will be randomly distributed in three groups. The first group will receive treatment with Cannabidiol 5%, the second group will receive treatment with Vivimind and the third group will not receive any treatment. The three groups will be compared by using an extensive neuropsychological examination and biomarkers' results from cerebrospinal fluid and blood

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of Mild Cognitive Impairment
  • Carry APOE ε4 gene

Exclusion

Exclusion Criteria:

  • Diagnosis of Dementia
  • Patients who receive medication for memory or depression
  • Patients who do not carry APOE ε4 gene

Study Design

Total Participants: 90
Study Start date:
April 01, 2021
Estimated Completion Date:
December 20, 2022

Connect with a study center

  • Greek Association of Alzheimer's Disease and Related Disorders

    Thessaloniki, 54248
    Greece

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.